Biosimilars: Technical and Regulatory Challenges Featured Report

Media Coverage
BI-000847

BioProcess International

“Currently there isn’t a well-defined reimbursement framework for biosimilars. Unless this is addressed swiftly and correctly, it is likely to undermine the sustainability of this new market.” Read more from Mario DiPaola, Sr. Scientific Director at Charles River, in BioProcess International’s recent blog post.

Read the blog post